In 2009, the European Society of Hypertension (ESH) has developed a document updating the recommendations for the diagnosis and treatment of hypertension issued in 2007. The main elements of novelty refer to the assessment of organ damage, the blood pressure thresholds for treatment initiation as well as the blood pressure goals, the use of drug combination treatment and the therapeutic intervention in specific clinical conditions. This paper will review the novelties of the ESH update document and the implications of the “new guidelines” for current clinical practice.
Keywords: Guidelines, antihypertensive treatment, clinical trials, blood pressure, control, Hypertension, non-cardiovascular disease, European Society of Cardiology, hypertension treatment, microalbuminuria, renal damage, Modification of Diet in Renal Disease, left ventricular hypertrophy, antihypertensive drug treatment, cardiovascular risk, diuretics, β-blockers, calcium antagonists, ace-inhibitors, angiotensin II receptor, systolic and diastolic blood pressure, Telmisartan, Ramipril, European Lacidipine Study on Atheroscle-rosis, renin, aliskiren, POLYPILL, aspirin, coronary heart disease
Acute Severe Arterial Hypertension: Therapeutic Options
Current Drug Targets How Should Serum Uric Acid Concentrations be Interpreted in Patients with Hypertension?
Current Hypertension Reviews Recent Developments in Drug Design of NO-donor Hybrid Compounds
Mini-Reviews in Medicinal Chemistry Genetics of Polygenic Hypertension from Animal Models to Humans
Current Hypertension Reviews Hydrochlorothiazide vs. Chlorthalidone as the Optimal Diuretic for the Management of Hypertension
Current Pharmaceutical Design Static Cerebral Blood Flow Autoregulation in Humans
Current Hypertension Reviews The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part III: Specific Management and Surgical Aspects
Current Cardiology Reviews Sildenafil Improves Vascular Endothelial Structure and Function in Renovascular Hypertension
Current Pharmaceutical Biotechnology Matrix Metalloproteinases in Vascular Disease - A Potential Therapeutic Target?
Current Vascular Pharmacology The Treatment of Cardiovascular Disease Continuum: Focus on Pharmacologic Management and RAS Blockade
Current Clinical Pharmacology Current Pharmacological Approach to Restore Endothelial Dysfunction
Cardiovascular & Hematological Agents in Medicinal Chemistry Nutraceutical Targeting of Placental Synthesis of Soluble Fms-Like Tyrosine Kinase- 1 (sFlt-1) as Strategy for Preventing and Controlling Pre-eclampsia
Current Pharmaceutical Design Smoking and Hypertension: Independent or Additive Effects to Determining Vascular Damage?
Current Vascular Pharmacology 2-Indolinone Derivatives as Potent Urease Inhibitors
Letters in Drug Design & Discovery Effects of Statins on Blood Pressure: A Review of the Experimental and Clinical Evidence.
Current Vascular Pharmacology Anti-Vascular Endothelial Growth Factor (VEGF) Therapy: A New Cause of Hypertension
Current Hypertension Reviews Arterial Thickness and Immunometabolism: The Mediating role of Chronic Exercise
Current Cardiology Reviews Hypoperfusion of the Aortic Wall Secondary to Degeneration of Adventitial Vasa Vasorum Causes Abdominal Aortic Aneurysms
Current Drug Targets Soluble Epoxide Hydrolase: A Novel Target for the Treatment of Hypertension
Recent Patents on Cardiovascular Drug Discovery (Discontinued) The Emergent Cardiovascular Risk Factors and Organ Damage in Arterial Hypertension
Current Hypertension Reviews